Clinical trial · Interventional
Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
NCT00997594CI-TRIAL-00017664completedPhase 2 / Phase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate changes in adrenal hormones during adrenal radiofrequency (RF) ablation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adrenal Tumors | Adrenal Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiofrequency ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Adrenal radiofrquency (RF) ablation
- description
- Patients who wll receive adrenal RF ablation.
- interventionNames
- Procedure: Radiofrequency ablation
- type
- ACTIVE_COMPARATOR
- label
- Abdominal RF ablation other than adrenal gland
- description
- Patients who will receive abdominal radiofrequency ablation other than adrenal gland.
- interventionNames
- Procedure: Radiofrequency ablation
Primary outcomes (3)
- measure
- Increase in Catecholamine
- timeFrame
- One day
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Unresectable adrenal tumor which will be treated by radiofrequency (RF)ablation * Blood pressure is 140mmHg or less before RF ablation * Age of 20-years or more * Performance status of 0 or 1 * Agreement from the patient Exclusion Criteria: * Platelet count of 50,000/mm\^3 or International normalized ratio (INR)\>1.5
References
Publications (0)
Data not yet available
No reference posted for this study.